Supernus Pharmaceuticals
SUPN
88 hedge funds and large institutions have $405M invested in Supernus Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 11 closing their positions.
258% more call options, than puts
Call options by funds: $9.1M | Put options by funds: $2.54M
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
36% more capital invested
Capital invested by funds: $298M → $405M (+$107M)
6% more funds holding
Funds holding: 83 → 88 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$12.8M |
| 2 |
MRM
Michael R. Murphy
|
+$10.3M |
| 3 |
OHCM
Orchard Hill Capital Management
New York
|
+$6.85M |
| 4 |
KIA
Kopp Investment Advisors
Bloomington,
Minnesota
|
+$4.44M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.75M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$2.74M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.23M |
| 4 |
MOACM
Mutual of America Capital Management
New York
|
-$2.18M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$2.14M |
SUPN Hedge Fund Activity: Q2 2014 in Review
88 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2014, worth a combined $405M — up 36% from $298M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SUPN positions and 11 closed out — a net gain of 5 holders — while 37 added to existing stakes and 25 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $12.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $6.75M.
- 88 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2014, up from 83 in Q1 2014.
- Funds reported $405M of Supernus Pharmaceuticals stock for Q2 2014, up 36% quarter-over-quarter.
- 16 funds opened new Supernus Pharmaceuticals positions in Q2 2014 and 11 closed out, a net change of +5 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2014 was Consonance Capital Management, an estimated $12.8M added.
- The largest Supernus Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $6.75M sold.
Based on aggregated 13F filings for Q2 2014.